Skip to main content
Top
Published in: Cancer Cell International 1/2020

01-12-2020 | Human Papillomavirus | Primary research

Identification of lysine acetylome in cervical cancer by label-free quantitative proteomics

Authors: Lu Zhang, Wanyue Wang, Shanqiang Zhang, Yuxin Wang, Weikang Guo, Yunduo Liu, Yaoxian Wang, Yunyan Zhang

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Lysine acetylation is a post-translational modification that regulates a diversity of biological processes, including cancer development.

Methods

Here, we performed the quantitative acetylproteomic analysis of three primary cervical cancer tissues and corresponding adjacent normal tissues by using the label-free proteomics approach.

Results

We identified a total of 928 lysine acetylation sites from 1547 proteins, in which 495 lysine acetylation sites corresponding to 296 proteins were quantified. Further, 41 differentially expressed lysine acetylation sites corresponding to 30 proteins were obtained in cervical cancer tissues compared with adjacent normal tissues (Fold change > 2 and P < 0.05), of which 1 was downregulated, 40 were upregulated. Moreover, 75 lysine acetylation sites corresponding to 58 proteins were specifically detected in cancer tissues or normal adjacent tissues. Motif-X analysis showed that kxxxkxxxk, GkL, AxxEk, kLxE, and kkxxxk are the most enriched motifs with over four-fold increases when compared with the background matches. KEGG analysis showed that proteins identified from differently and specifically expressed peptides may influence key pathways, such as Notch signaling pathway, viral carcinogenesis, RNA transport, and Jak-STAT, which play an important role in tumor progression. Furthermore, the acetylated levels of CREBBP and S100A9 in cervical cancer tissues were confirmed by immunoprecipitation (IP) and Western blot analysis.

Conclusions

Taken together, our data provide novel insights into the role of protein lysine acetylation in cervical carcinogenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.CrossRef Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.CrossRef
2.
go back to reference Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18(12):1579–89.CrossRef Fidler MM, Gupta S, Soerjomataram I, Ferlay J, Steliarova-Foucher E, Bray F. Cancer incidence and mortality among young adults aged 20–39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18(12):1579–89.CrossRef
3.
go back to reference Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015;350:h2372.CrossRef Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015;350:h2372.CrossRef
4.
go back to reference Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015;15(10):1171–81.CrossRef Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015;15(10):1171–81.CrossRef
5.
go back to reference Brucker SY, Ulrich UA. Surgical treatment of early-stage cervical cancer. Oncol Res Treat. 2016;39(9):508–14.CrossRef Brucker SY, Ulrich UA. Surgical treatment of early-stage cervical cancer. Oncol Res Treat. 2016;39(9):508–14.CrossRef
6.
go back to reference Mallmann P, Mallmann C. Neoadjuvant and adjuvant chemotherapy of cervical cancer. Oncol Res Treat. 2016;39(9):522–4.CrossRef Mallmann P, Mallmann C. Neoadjuvant and adjuvant chemotherapy of cervical cancer. Oncol Res Treat. 2016;39(9):522–4.CrossRef
7.
go back to reference Aasen T, Johnstone S, Vidal-Brime L, Lynn KS, Koval M. Connexins: synthesis, post-translational modifications, and trafficking in health and disease. Int J Mol Sci. 2018;19(5):1296.CrossRef Aasen T, Johnstone S, Vidal-Brime L, Lynn KS, Koval M. Connexins: synthesis, post-translational modifications, and trafficking in health and disease. Int J Mol Sci. 2018;19(5):1296.CrossRef
8.
go back to reference Kori Y, Sidoli S, Yuan ZF, Lund PJ, Zhao X, Garcia BA. Proteome-wide acetylation dynamics in human cells. Sci Rep. 2017;7(1):10296.CrossRef Kori Y, Sidoli S, Yuan ZF, Lund PJ, Zhao X, Garcia BA. Proteome-wide acetylation dynamics in human cells. Sci Rep. 2017;7(1):10296.CrossRef
9.
go back to reference Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–8.CrossRef Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;417(6887):455–8.CrossRef
10.
go back to reference Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA. 2002;99(21):13653–8.CrossRef Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA. 2002;99(21):13653–8.CrossRef
11.
go back to reference Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006;23(4):607–18.CrossRef Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006;23(4):607–18.CrossRef
12.
go back to reference Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–40.CrossRef Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–40.CrossRef
13.
go back to reference Kaypee S, Sudarshan D, Shanmugam MK, Mukherjee D, Sethi G, Kundu TK. Aberrant lysine acetylation in tumorigenesis: implications in the development of therapeutics. Pharmacol Ther. 2016;162:98–119.CrossRef Kaypee S, Sudarshan D, Shanmugam MK, Mukherjee D, Sethi G, Kundu TK. Aberrant lysine acetylation in tumorigenesis: implications in the development of therapeutics. Pharmacol Ther. 2016;162:98–119.CrossRef
14.
go back to reference Gil J, Ramirez-Torres A, Encarnacion-Guevara S. Lysine acetylation and cancer: a proteomics perspective. J Proteomics. 2017;150:297–309.CrossRef Gil J, Ramirez-Torres A, Encarnacion-Guevara S. Lysine acetylation and cancer: a proteomics perspective. J Proteomics. 2017;150:297–309.CrossRef
15.
go back to reference Tafrova JI, Tafrov ST. Human histone acetyltransferase 1 (Hat1) acetylates lysine 5 of histone H2A in vivo. Mol Cell Biochem. 2014;392(1–2):259–72.CrossRef Tafrova JI, Tafrov ST. Human histone acetyltransferase 1 (Hat1) acetylates lysine 5 of histone H2A in vivo. Mol Cell Biochem. 2014;392(1–2):259–72.CrossRef
16.
go back to reference Zhu D, Hou L, Hu B, Zhao H, Sun J, Wang J, et al. Crosstalk among proteome, acetylome and succinylome in colon cancer HCT116 cell treated with sodium dichloroacetate. Sci Rep. 2016;6:37478.CrossRef Zhu D, Hou L, Hu B, Zhao H, Sun J, Wang J, et al. Crosstalk among proteome, acetylome and succinylome in colon cancer HCT116 cell treated with sodium dichloroacetate. Sci Rep. 2016;6:37478.CrossRef
17.
go back to reference Tatham MH, Cole C, Scullion P, Wilkie R, Westwood NJ, Stark LA, et al. A proteomic approach to analyze the aspirin-mediated lysine acetylome. Mol Cell Proteomics. 2017;16(2):310–26.CrossRef Tatham MH, Cole C, Scullion P, Wilkie R, Westwood NJ, Stark LA, et al. A proteomic approach to analyze the aspirin-mediated lysine acetylome. Mol Cell Proteomics. 2017;16(2):310–26.CrossRef
18.
go back to reference Gu X, Hua Z, Dong Y, Zhan Y, Zhang X, Tian W, et al. Proteome and acetylome analysis identifies novel pathways and targets regulated by perifosine in neuroblastoma. Sci Rep. 2017;7:42062.CrossRef Gu X, Hua Z, Dong Y, Zhan Y, Zhang X, Tian W, et al. Proteome and acetylome analysis identifies novel pathways and targets regulated by perifosine in neuroblastoma. Sci Rep. 2017;7:42062.CrossRef
19.
go back to reference Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389(6649):349–52.CrossRef Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997;389(6649):349–52.CrossRef
20.
go back to reference Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277(1):8–21.CrossRef Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277(1):8–21.CrossRef
21.
go back to reference Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–76.CrossRef Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–76.CrossRef
22.
go back to reference Zhang H, Shang YP, Chen HY, Li J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. 2017;47(2):149–59.CrossRef Zhang H, Shang YP, Chen HY, Li J. Histone deacetylases function as novel potential therapeutic targets for cancer. Hepatol Res. 2017;47(2):149–59.CrossRef
23.
go back to reference Valor LM, Viosca J, Lopez-Atalaya JP, Barco A. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des. 2013;19(28):5051–64.CrossRef Valor LM, Viosca J, Lopez-Atalaya JP, Barco A. Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. Curr Pharm Des. 2013;19(28):5051–64.CrossRef
24.
go back to reference Stachowiak MK, Birkaya B, Aletta JM, Narla ST, Benson CA, Decker B, et al. Nuclear FGF receptor-1 and CREB binding protein: an integrative signaling module. J Cell Physiol. 2015;230(5):989–1002.CrossRef Stachowiak MK, Birkaya B, Aletta JM, Narla ST, Benson CA, Decker B, et al. Nuclear FGF receptor-1 and CREB binding protein: an integrative signaling module. J Cell Physiol. 2015;230(5):989–1002.CrossRef
25.
go back to reference Liu Y, Wang L, Han R, Beier UH, Akimova T, Bhatti T, et al. Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3 + T-regulatory cell development and function. Mol Cell Biol. 2014;34(21):3993–4007.CrossRef Liu Y, Wang L, Han R, Beier UH, Akimova T, Bhatti T, et al. Two histone/protein acetyltransferases, CBP and p300, are indispensable for Foxp3 + T-regulatory cell development and function. Mol Cell Biol. 2014;34(21):3993–4007.CrossRef
26.
go back to reference Cai K, Wan Y, Wang Z, Wang Y, Zhao X, Bao X. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation. Oncol Rep. 2014;32(5):2260–6.CrossRef Cai K, Wan Y, Wang Z, Wang Y, Zhao X, Bao X. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation. Oncol Rep. 2014;32(5):2260–6.CrossRef
27.
go back to reference Cazzalini O, Sommatis S, Tillhon M, Dutto I, Bachi A, Rapp A, et al. CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis. Nucleic Acids Res. 2014;42(13):8433–48.CrossRef Cazzalini O, Sommatis S, Tillhon M, Dutto I, Bachi A, Rapp A, et al. CBP and p300 acetylate PCNA to link its degradation with nucleotide excision repair synthesis. Nucleic Acids Res. 2014;42(13):8433–48.CrossRef
28.
go back to reference Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. Chem Rev. 2015;115(6):2419–52.CrossRef Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. Chem Rev. 2015;115(6):2419–52.CrossRef
29.
go back to reference Jansma AL, Martinez-Yamout MA, Liao R, Sun P, Dyson HJ, Wright PE. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb. J Mol Biol. 2014;426(24):4030–48.CrossRef Jansma AL, Martinez-Yamout MA, Liao R, Sun P, Dyson HJ, Wright PE. The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb. J Mol Biol. 2014;426(24):4030–48.CrossRef
30.
go back to reference Jia Y, Nie F, Du A, Chen Z, Qin Y, Huang T, et al. Thymine DNA glycosylase promotes transactivation of beta-catenin/TCFs by cooperating with CBP. J Mol Cell Biol. 2014;6(3):231–9.CrossRef Jia Y, Nie F, Du A, Chen Z, Qin Y, Huang T, et al. Thymine DNA glycosylase promotes transactivation of beta-catenin/TCFs by cooperating with CBP. J Mol Cell Biol. 2014;6(3):231–9.CrossRef
31.
go back to reference Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, et al. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth. Oncotarget. 2015;6(10):8046–61.CrossRef Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, et al. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth. Oncotarget. 2015;6(10):8046–61.CrossRef
32.
go back to reference Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, et al. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther. 2014;13(10):2303–14.CrossRef Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, et al. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther. 2014;13(10):2303–14.CrossRef
33.
go back to reference Gajer JM, Furdas SD, Grunder A, Gothwal M, Heinicke U, Keller K, et al. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis. 2015;4:e137.CrossRef Gajer JM, Furdas SD, Grunder A, Gothwal M, Heinicke U, Keller K, et al. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis. 2015;4:e137.CrossRef
34.
go back to reference Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, et al. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene. 2016;35(3):279–89.CrossRef Giotopoulos G, Chan WI, Horton SJ, Ruau D, Gallipoli P, Fowler A, et al. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia. Oncogene. 2016;35(3):279–89.CrossRef
Metadata
Title
Identification of lysine acetylome in cervical cancer by label-free quantitative proteomics
Authors
Lu Zhang
Wanyue Wang
Shanqiang Zhang
Yuxin Wang
Weikang Guo
Yunduo Liu
Yaoxian Wang
Yunyan Zhang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01266-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine